For Immediate Release
Chicago, IL – February 23, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: NVIDIA Corp.
NVDA
, Novartis AG
NVS
, NextEra Energy, Inc.
NEE
, The Goldman Sachs Group, Inc.
GS
and Amgen Inc.
AMGN
.
Here are highlights from Tuesday’s Analyst Blog:
Top Stock Reports for NVIDIA, Novartis and NextEra Energy
The Zacks Research Daily presents the best research output of our analyst team. Today’s Research Daily features new research reports on 16 major stocks, including
NVIDIA Corp.
,
Novartis AG
and
NextEra Energy, Inc
. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see
all of today’s research reports here >>>
Shares of
NVIDIA
have outperformed the Zacks Semiconductor – General industry over the past year (+67.2% vs. +21.4%). The Zacks analyst believes that NVIDIA is benefiting from coronavirus-induced work and learn-from-home wave. It is also benefiting from strong growth in GeForce desktop and notebook Graphic Processing Units, which is boosting gaming revenues. Moreover, a surge in Hyperscale demand remains a tailwind for the company’s Data Center business.
Expansion of NVIDIA GeForce NOW is expected to drive user base. Further, solid uptake of artificial intelligence-based smart cockpit infotainment solutions is a boon. Additionally, collaboration with Mercedes-Benz is expected to further strengthen NVIDIA’s presence in the autonomous vehicles and other automotive electronics space. However, management expects COVID-19 pandemic to negatively impact near-term revenues. Moreover, the U.S.-China trade war remains a key concern.
(You can
read the full research report on NVIDIA here >>>
)
Shares of
Novartis
have underperformed the Zacks Large Cap Pharmaceuticals industry over the past year (-0.2% vs. +16.9%), however the company still has a strong and diverse portfolio. The Zacks analyst believes that solid momentum in key brands like psoriasis drug Cosentyx, cardiovascular drug Entresto, gene therapy Zolgensma, the oncology portfolio and the launch of Kesimpta should continue to boost performance after a slowdown earlier in the year.
The launch of additional drugs like Piqray, Leqvio and Mayzent and the label expansion of key drugs should boost performance. The pipeline progress is impressive and the company has some promising candidates.
However, the Sandoz division continues to be a drag on the overall business due to pricing pressures. Hence, management has commenced a strategic review of Sandoz and might separate the business. Generic competition for key drugs and pipeline setbacks also pose concerns.
(You can
read the full research report on Novartis here >>>
)
Shares of
NextEra Energy
have underperformed the Zacks Utility – Electric Power industry over the past six month period (-12.1% vs. -4.0%), but the Zacks analyst believes that the company through solid execution of organic projects and strategic acquisitions — is on course to achieve long-term growth objectives.
NextEra currently has a lot of renewable projects in its backlog and the number is rising every quarter, which is aiding NextEra to reduce emissions. The merger of Gulf Power and FPL further strengthens NextEra’s position in Florida. Improving Florida economy and NEE’s reliable energy services is expanding its customer volume in every quarter.
NextEra has ample liquidity to meet the current debt obligations. However, nature of its business is subject to complex federal, state and other regulations. Unfavorable weather conditions and an increase in supply costs adversely impact earnings.
(You can
read the full research report on NextEra Energy here >>>
)
Other noteworthy reports we are featuring today include
The Goldman Sachs Group, Inc.
and
Amgen Inc.
Just Released: Zacks Top 10 Stocks for 2022
In addition to the investment ideas discussed above, would you like to know about our 10 top buy-and-hold tickers for the entirety of 2022?
Last year’s 2021
Zacks Top 10 Stocks
portfolio returned gains as high as +147.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys
Access Zacks Top 10 Stocks for 2022 today >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss
.
This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit
https://www.zacks.com/performance
for information about the performance numbers displayed in this press release.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +25.4% per year.
These 7 were selected because of their superior potential for immediate breakout.
See these time-sensitive tickers now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
